MASI vs PATH · rev $2.09B vs P/E 19, rev $1.61B
Masimo Corporation (MASI) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Masimo Corporation (MASI) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported MASI revenue for 2024-12-28 was $2.09B. Net income was -$304.9M. Revenue was up 2.3% from 2023-12-30 to 2024-12-28. MASI currently screens at market cap $9.02B.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
MASI currently screens at market cap $9.02B. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the MASI and PATH stock pages for the full models.
Not investment advice.